Adapting the prevalent new-user study design and clone-censor-weighting approach to evaluate drug discontinuation
- 5 October 2026
- journal article
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
Abstract
We described how to adapt the prevalent new-user (PNU) study design to estimate the effect of drug discontinuation among patients who discontinue and clone-censor-weighting (CCW) approach to estimate the effect of drug discontinuation among an eligible population at a pre-specified time point, focusing on the differences between the target trials the 2 approaches emulate. While both approaches produced unbiased estimates of the effect of drug discontinuation when all confounders were adjusted for in simulations, the true estimands differed, particularly when treatment effect heterogeneity was introduced. We also applied the approaches to study the effect of statin discontinuation among United States Medicare beneficiaries who discontinued statin therapy after at least 5 years (PNU) or at approximately 5 years (CCW) of continuous use. The PNU analysis estimated a mortality rate difference (MRD) of 3.6 (95% CI, 3.3-3.9) per 100 person-years and a mortality rate ratio (MRR) of 1.41 (95% CI, 1.37-1.45), while the CCW analysis estimated a MRD of 3.4 (95% CI, 2.8-4.0) per 100 person-years and MRR of 1.55 (1.45-1.66). Researchers studying drug discontinuation should carefully consider their causal question and target population when choosing between these 2 newer approaches.Keywords
Funding Information
- American Diabetes Association (1-25-PDF-96)
- National Institute of Diabetes and Digestive and Kidney Disease (F32-DK-143-609)
- National Institute on Aging of the National Institutes of Health (R01AG056479)
This publication has 20 references indexed in Scilit:
- Comparing causal estimands from sequential nested versus single point target trials: a simulation studyAmerican Journal of Epidemiology, 2026
- Core Concepts in Pharmacoepidemiology: New‐User DesignsPharmacoepidemiology and Drug Safety, 2024
- Can Observational Analyses of Routinely Collected Data Emulate Randomized Trials? Design and Feasibility of the Observational Patient Evidence for Regulatory Approval Science and Understanding Disease ProjectValue in Health, 2022
- Methods for evaluating the benefit and harms of deprescribing in observational research using routinely collected dataResearch in Social and Administrative Pharmacy, 2022
- Statin Discontinuation and Cardiovascular Events Among Older People in DenmarkJAMA Network Open, 2021
- Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving PolypharmacyJAMA Network Open, 2021
- Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCIJAMA, 2019
- Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scoresPharmacoepidemiology and Drug Safety, 2016
- Safety and Benefit of Discontinuing Statin Therapy in the Setting of Advanced, Life-Limiting IllnessJAMA Internal Medicine, 2015
- A Comparison of Observational Studies and Randomized, Controlled TrialsNew England Journal of Medicine, 2000